Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-09-2014 | Case Report

A Paroxysmal Nocturnal Haemoglobinuria Progress with Waldenström Macroglobulinemia Along with T Cell Monoclonal Expansion

Authors: Hongying Liu, Chuan He, Huanling Zhu, Xianglong Li, Chunli Yang, Dewan Zhao, Xiujin Wu

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell clinical disease, which has been reported associated with T cell monoclonal expansion and plasma cell dyscrasias. There we reported a case with a 20-year clinical history of PNH. Lately diagnosis of Waldenström macroglobulinemia with the offered evidences of bone marrow examination, flow cytometry and immunofixation electrophoresis. T cell monoclonal expansion was established by polymerase chain reaction. Meanwhile the decreased expression of CD55 and CD59 on neutrophils and erythrocyte were obvious observed. Here we describe the diagnostic evaluation of this patient and provide a brief review of such clonal disorder.

Risitano AM, Rotoli B (2008) Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics 2(2):205–222PubMedPubMedCentral

Pu JJ, Brodsky RA (2011) Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci 4(3):219–224PubMedCrossRefPubMedCentral

Araten DJ, Luzzatto L (2006) The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108:734–736PubMedCrossRefPubMedCentral

Cornélis F, Montfort L, Osselaer JC et al (1996) Acute leukaemia in paroxysmal nocturnal haemoglobinuria. Case report and review of the literature. Hematol Cell Ther 38:285–288PubMedCrossRef

Régis Peffault de Latour, Jean Yves Mary, Célia Salanoubat et al (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112:3099–3106

Meletis J, Terpos E, Samarkos M et al (2002) Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias. Int J Hematol 75:40–44PubMedCrossRef

van Dongen JJM, Langerak AW, Bruggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombination in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257–2317PubMedCrossRef

Bor Owitz MJ, Craig FE et al (2010) A guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B 78B:211–230

Treon Steven P (2009) How I treat waldenström macroglobulinemia. Blood 114:2375–2385PubMedCrossRef

10.

Nyland SB, Krissinger DJ, Clemente MJ et al (2012) Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res 36(5):581–587PubMedCrossRefPubMedCentral

11.

Wlodarski MW, Lukasz P et al (2006) Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 108:2632–2641PubMedCrossRefPubMedCentral

12.

Gargiulo L, Lastraioli S, Cerruti G et al (2007) Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 109:5036–5042PubMedCrossRef

13.

Risitano AM, Maciejewski JP, Muranski P et al (2005) Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia 19:217–222PubMedCrossRef

14.

Karadimitris A, Manavalan JS, Howard T et al (2000) Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 96:2613–2620PubMed

Title: A Paroxysmal Nocturnal Haemoglobinuria Progress with Waldenström Macroglobulinemia Along with T Cell Monoclonal Expansion
Authors: Hongying Liu
Chuan He
Huanling Zhu
Xianglong Li
Chunli Yang
Dewan Zhao
Xiujin Wu
Publication date: 01-09-2014
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-014-0337-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Hb Knossos: HBB:c.82G>T Associated with HBB:c.315+1G>A Beta Zero Mutation Causes Thalassemia Intermedia

Granulocyte Colony Stimulating Factor Induced Sweet’s Syndrome Following Autologous Transplantation in a Child with Relapsed Acute Myeloblastic Leukemia

Acute Human Parvovirus B19 Infection: Cytologic Diagnosis

Histiocytic Sarcoma with Acute Lymphoblastic Leukemia a Rare Association: Case Report and Literature Review

Acute Myeloid Leukemia with BCR/ABL Fusion Chimera

Hemophagocytic Lymphohistiocytosis Associated with Cytomegalovirus Infection in an Immunocompetent Infant: A Diagnostic and Therapeutic Challenge!

Keynote webinar | Spotlight on antibody–drug conjugates in cancer